Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBUILD-1: Galcanezumab in Children and Adolescents with Episodic Migraine
2023-505836-36-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine headache days. Planned start Nov 2023; status: authorised.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2023-505836-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505836-36-00.